Founded Year
1962Stage
PIPE - II | IPOAbout MultiCell Technologies
MultiCell Technologies is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.
Missing: MultiCell Technologies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: MultiCell Technologies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing MultiCell Technologies
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
MultiCell Technologies is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
1,568 items
MultiCell Technologies Patents
MultiCell Technologies has filed 2 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/1/2011 | 8/19/2014 | Immune system, Immunology, Clusters of differentiation, Human cells, T cells | Grant |
Application Date | 4/1/2011 |
|---|---|
Grant Date | 8/19/2014 |
Title | |
Related Topics | Immune system, Immunology, Clusters of differentiation, Human cells, T cells |
Status | Grant |
Latest MultiCell Technologies News
Jul 25, 2020
MultiCell Technologies (MEDS) Scheduled to Post Quarterly Earnings on Monday Posted by Amber O'Connor on Jul 25th, 2020 Daily Ratings & News for MultiCell Technologies Complete the form below to receive the latest headlines and analysts' recommendations for MultiCell Technologies with our free daily email newsletter: MultiCell Technologies (NASDAQ:MEDS) is scheduled to be posting its quarterly earnings results after the market closes on Monday, July 27th. Analysts expect MultiCell Technologies to post earnings of $0.01 per share for the quarter. MultiCell Technologies (NASDAQ:MEDS) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.02 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.02. MultiCell Technologies had a negative net margin of 2.82% and a negative return on equity of 4.81%. The business had revenue of $2.20 million during the quarter. On average, analysts expect MultiCell Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year. Get MultiCell Technologies alerts: NASDAQ:MEDS opened at $6.04 on Friday. The firm has a market capitalization of $48.20 million, a P/E ratio of 201.33, a P/E/G ratio of 1.67 and a beta of 1.31. The business’s fifty day moving average is $6.03. MultiCell Technologies has a 12 month low of $3.30 and a 12 month high of $11.60. The company has a quick ratio of 9.91, a current ratio of 10.30 and a debt-to-equity ratio of 0.09. A number of research firms have weighed in on MEDS. Dougherty & Co reaffirmed a “buy” rating and issued a $12.00 price objective on shares of MultiCell Technologies in a report on Thursday, April 30th. Taglich Brothers reissued a “speculative buy” rating on shares of MultiCell Technologies in a research note on Wednesday, June 10th. Finally, Zacks Investment Research cut shares of MultiCell Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, May 30th. About MultiCell Technologies Trxade Group, Inc owns and operates a business-to-business Web-based marketplace focused on the pharmaceutical industry in the United States. It operates through Trxade, Inc; Community Specialty Pharmacy, LLC; and Other segments. The company operates a Web based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services.
MultiCell Technologies Frequently Asked Questions (FAQ)
When was MultiCell Technologies founded?
MultiCell Technologies was founded in 1962.
Where is MultiCell Technologies's headquarters?
MultiCell Technologies's headquarters is located at 68 Cumberland Street, Woonsocket.
What is MultiCell Technologies's latest funding round?
MultiCell Technologies's latest funding round is PIPE - II.
Who are the investors of MultiCell Technologies?
Investors of MultiCell Technologies include M.A.G. Capital, Fusion Capital Partners and Marr Technologies Bv.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.